Interestingly, melanoma cells harvested from the three mice that responded for 50 days after ADC treatment remained sensitive to anti-CSPG4-(PDD) treatment ex vivo compared with A375 tumor cells harvested from the isotype-(PDD) treatment mouse. Here, CSPG4 is linked to neoplasm.